/
We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard-of-care ("SoC") therapeutics.
The business is unprofitable at the operating level (-8256.32% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 13.2% YoY. Margins deteriorated 1133.2pp alongside, both lines moving the wrong way.
ROIC dropped from -49.16% to -59.19%, capital efficiency is deteriorating. Negative free cash flow of -$38M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$525K
▼ -13.2% YoY
Net Income (TTM)
-$45M
▼ -0.9% YoY
Op. Margin
-9033.90%
▼ -1133.2pp YoY
ROIC
-78.40%
▼ -10.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$37M
▼ -0.5% YoY
Op. Cash Flow (TTM)
-$37M
▼ -0.6% YoY
Net Debt
-$45M
Net Cash Position
Cash & Equiv.
$46M
5Y CAGR: +10.1%
Continue Research